Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- OrphanPacific Voluntarily Recalls Buphenyl Tablets
March 24, 2014
- Hospira Voluntarily Recalls 9 Generic Anticancer Agents Due to Incomplete Labeling
March 24, 2014
- Maruho Files NDA for Acne Drug in Japan
March 20, 2014
- Astellas Seeks US Approval for Additional Indication of Enzalutamide
March 20, 2014
- Astellas, Daiichi Sankyo Hook Up in Compound Library Sharing
March 20, 2014
- Galderma Files NDA for Cancer Odor Treatment
March 20, 2014
- Eli Lilly Japan Sales Up 9% in 2013
March 19, 2014
- Sanofi Settles Allegra Generic Suit with Elmed Eisai, Kobayashi Kako
March 19, 2014
- Daiichi Sankyo Files NDA for Methylene Blue for Methemoglobinemia
March 19, 2014
- Genzyme Asia Pacific Senior VP to Run Japan Operations
March 18, 2014
- Novartis Workers were Acting for Office of SIGN Trial Initiator Group: University of Tokyo
March 17, 2014
- Bayer Yakuhin Chairman Eiki to Step Down
March 17, 2014
- LEO Pharma to Carefully Ponder When to Begin Solo Marketing in Japan: Local Head
March 14, 2014
- Nichi-Iko to Name Company Succeeded from Astellas “Nichi-Iko Pharma Tech”
March 14, 2014
- Takeda to Abolish CCO Post, Commercial Operations to Come Directly Under Weber’s Control
March 14, 2014
- Will Original Drug Makers Suddenly Embrace AGs? Comments of MHLW Official Could Spark Big Changes
March 14, 2014
- Otsuka to Disclose Patient-Level Clinical Trial Data
March 13, 2014
- Santen to Create New Exec Posts to Accelerate Globalization
March 13, 2014
- Novartis Japan Sales Tick Up 0.8%, Diovan Down 13%, Tasigna Up 35%
March 13, 2014
- Torii Confirms Positive Results from PII/III Study of Investigational Allergen Immunotherapy Treatment TO-203
March 13, 2014
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…